New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—

KARDIGAN INC 10-Q filed Aug 11, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 7:10 AM ET · Document on sec.gov · Filing index

Read the filing on sec.gov

Nothing in this filing raised a red flag. The document itself is on sec.gov.